Today's Stock Analyst Downgrades

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
BMRC Bank of Marin Bancorp	Downgraded by	Brean Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$29.10 -4.0%	$33.00	Buy ➝ Neutral
CLX Clorox	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kaumil Gajrawala Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$100.50 +3.2%	$125.00 ➝ $98.00	Buy ➝ Hold
EBC Eastern Bankshares	Downgraded by	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Breese Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$23.55 +1.9%	$24.00	Overweight ➝ Equal Weight
FBRX Forte Biosciences	Downgraded by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Etzer Darout Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$76.65 +0.2%	$74.00 ➝ $77.00	Overweight ➝ Equal Weight
FMS Fresenius Medical Care AG & Co. KGaA	Downgraded by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$24.76 -0.5%	$19.90	Neutral ➝ Underperform
INTU Intuit	Downgraded by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Levine Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$312.99 +3.0%	$504.00 ➝ $304.00	Buy ➝ Hold
ISRG Intuitive Surgical	Downgraded by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mathew Blackman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$361.80 +1.4%		Buy ➝ Hold
PODD Insulet	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$167.47 +1.5%	$174.00	Buy ➝ Neutral
PRCT PROCEPT BioRobotics	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$18.08 +2.2%	$20.00	Buy ➝ Neutral
PYPL PayPal	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Timothy Chiodo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$58.32 +4.0%		Neutral ➝ Hold
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
SIGI Selective Insurance Group	Downgraded by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Zaremski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$94.40 +1.7%	$97.00	Outperform ➝ Market Perform
SYRE Spyre Therapeutics	Downgraded by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$99.96 -0.1%		Outperform ➝ Peer Perform
VC Visteon	Downgraded by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emmanuel Rosner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$106.93 +1.3%		Outperform ➝ Peer Perform
XOM ExxonMobil	Downgraded by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jean Ann Salisbury Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$153.20 -1.0%	$154.00 ➝ $158.00	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:51 PM ET.

Frequently Asked Questions

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

Stock Analyst Downgrades

Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stock Analyst Downgrades

Frequently Asked Questions

What are analyst ratings?

Should you trust analyst ratings?

What does an analyst rating tell you about a stock?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools